DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Friday. The brokerage set a “hold” rating on the stock.

Separately, JMP Securities reaffirmed a “market outperform” rating and issued a $10.00 target price on shares of DBV Technologies in a research report on Friday, January 10th.

DBV Technologies Stock Down 6.5 %

NASDAQ DBVT opened at $4.87 on Friday. The stock has a market cap of $100.17 million, a PE ratio of -1.08 and a beta of 0.71. DBV Technologies has a fifty-two week low of $2.20 and a fifty-two week high of $8.32. The business has a 50 day moving average price of $4.37 and a two-hundred day moving average price of $3.82.

Hedge Funds Weigh In On DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC purchased a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies at the end of the most recent quarter. 71.74% of the stock is currently owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.